Table 2: Randomization, data collection, analyses and results Ref a) Randomization type b) N, n-intervention, and n-control

Similar documents
Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Introduction Objective Methods Results Conclusion

Service delivery interventions

Prostate Cancer Patients Report on Benefits of Proton Therapy

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Cancer research in the Midland Region the prostate and bowel cancer projects

Clinical Spotlight in Breast Cancer

Randomized trials versus observational studies

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes. Dr Paul Beckett Royal Derby Hospital

Karen B. Hirschman, PhD MSW Research Assistant Professor School of Nursing. Geriatric Grand Rounds Friday, December 9, 2011 TRANSITIONS

Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Psychological Well-being of Women With Metastatic Breast. Innovative a Community Supportive-Expressive Group in a Community Setting

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan

Effect of Anxiety or Depression on Cancer Screening among Hispanic Immigrants

Disclosure. I have the following relationships with commercial interests:

Screening for psychological distress in inoperable lung cancer patients: an evaluation of the Brief Distress Thermometer (BDT)

National Hospice Social Work Survey

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

Survivorship Care Plans Guides for Living After Cancer Treatment

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Organizing Your Approach to a Data Analysis

Management of low grade glioma s: update on recent trials

Introduction to Statistics Used in Nursing Research

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Personalized Predictive Medicine and Genomic Clinical Trials

HMRC Tax Credits Error and Fraud Additional Capacity Trial. Customer Experience Survey Report on Findings. HM Revenue and Customs Research Report 306

Introduction. Survival Analysis. Censoring. Plan of Talk

Aaisha Ghauri Savvas Amber Curry

Hospice and Palliative Care: Help Throughout Life s Journey. John P. Langlois MD CarePartners Hospice and Palliative Care

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

The Cross-Sectional Study:

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations

[Author Name]. (2014, June). [Title of Presentation]. Podium presentation at the 7th Biennial Cancer Survivorship Research Conference, Atlanta, GA.

The Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool

Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up

Annicka G. M. van der Plas. Kris C. Vissers. Anneke L. Francke. Gé A. Donker. Wim J. J. Jansen. Luc Deliens. Bregje D. Onwuteaka-Philipsen

ductal carcinoma in situ (DCIS)

Understanding ductal carcinoma in situ (DCIS) and deciding about treatment

Marina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer

Kanıt: Klinik çalışmalarda ZYTIGA

The ACC 50 th Annual Scientific Session

Diabetes Prevention in Latinos

Efficacy analysis and graphical representation in Oncology trials - A case study

November 15, Ann Laramee MS ANP-BC ACNS-BC CHFN FletcherAllen.org

What is Palliative Care

Austen Riggs Center Patient Demographics

RED, BOOST, and You: Improving the Discharge Transition of Care

Presented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention

Department of Psychiatry, The University of Melbourne

Methods for Meta-analysis in Medical Research

Passport Advantage Provider Manual Section 10.0 Care Management Table of Contents

Success factors in Behavioral Medicine

Data Analysis, Research Study Design and the IRB

Study Design and Statistical Analysis

A new score predicting the survival of patients with spinal cord compression from myeloma

Breast Cancer Care & Research

13. Poisson Regression Analysis

DECISION AND SUMMARY OF RATIONALE

Elementary Statistics

Electronic health records to study population health: opportunities and challenges

IBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS. Oye Gureje Professor of Psychiatry University of Ibadan Nigeria

Oncology Medical Home Measure Specification Data

A PROSPECTIVE EVALUATION OF THE RELATIONSHIP BETWEEN REASONS FOR DRINKING AND DSM-IV ALCOHOL-USE DISORDERS

The Patient Journey in High Resolution

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Meleis Theory of Transition

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

SOLUTIONS TO BIOSTATISTICS PRACTICE PROBLEMS

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)

How To Know If You Have Cancer At Mercy Regional Medical Center

Quality of Life of Children

With Depression Without Depression 8.0% 1.8% Alcohol Disorder Drug Disorder Alcohol or Drug Disorder

How valuable is a cancer therapy? It depends on who you ask.

indicates that the relationship between psychosocial distress and disability in patients with CLBP is not uniform.

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)

VIEW FROM WASHINGTON. Judi Lund Person, MPH Vice President, Compliance and Regulatory Leadership, NHPCO

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years

Secure Messaging Evidence Table

Guidance on competencies for management of Cancer Pain in adults

EDUCATING, SUPPORTING & COORDINATING CARE: ONCOLOGY NURSE NAVIGATORS

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us

2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.

Patient Reported Outcome Measures (PROMs) in England: Update to reporting and case-mix adjusting hip and knee procedure data.

Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer

SAMPLE DESIGN RESEARCH FOR THE NATIONAL NURSING HOME SURVEY

Can I have FAITH in this Review?

Care Guide: Cancer Distress Management

Data Management, Audit and Outcomes of the NHS

Trends in psychosocial working conditions : Evidence of narrowing inequalities?

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer

Transcription:

Table 2: Randomization, data collection, analyses and results Ref [19] a) Stratified, cluster (stratification at surgeon level (experience of surgeon s breast cancer practice); Within each stratum randomization was performed in blocks of four. b) N(Surgeons)=60; N(Patients)=335, n- CM=169, n-control=166 [23] a) Simple, two-arm randomization. b) N=210, n-int=106, n- control=104 Primary: cancer-specific therapies received (after 6 months) Secondary: patient evaluations of the decisionmaking process; arm function on affected side. (2 (and 12) months after diagnosis.) -Quality of Life (QoL) (At enrolment + 1, 3, 6, 12, 18, 24 months after enrolment.) -Cost data (24 months after date of diagnosis). Primary: medical records audit (A summary measure of receipt of appropriate therapy was created based on published consensus recommendations; ref) Secondary: home interview based on pilot tested questionnaires on logistics, decision-making, satisfaction and tamoxifen prescription (?) and objective assessment of arm functions (?). -QoL measured with three selfadministered questionnaires: 1. MUIS: uncertainty 2. POMS: mood 3. FACT-E: well-being/ QoL on six dimensions. (yes, all validated + ref) -Charges and reimbursements were collected from billing systems. Length of hospitalization and number of visit to health care provider were recorded. a) Differences in baseline characteristics and in outcomes between control and intervention groups were assessed using chi-square. (Cluster effect at surgeon level was adjusted for.) b) Yes. No difference found (demographics, cognitive function, and stage of disease) c) Primary outcome: n-cm: 169 and n- control 166 Secondary outcomes:? d) Yes a) -Univariate analyses of QoL data: t- test + chi-square /Fisher s exact test. Multiple regression for repeated QoL measures using baseline scores as a covariate. -Costs: Univariate analysis + multivariate regression. b) Yes (variables: demographics and disease characteristics). Difference found: Intervention group women had lower histology (p=0,04) and more received adjuvant hormone therapy (p=0,03); adj. performed. Primary: More women in the intervention group saw a radiation oncologist at their initial evaluation (36.0 vs. 19.3%, P=0.006), received breast-conserving surgery (28.6 vs. 18.7%, p=0.031) and radiation therapy (36.0% vs. 19.0%; P=0.003). Secondary: Intervention group was significantly more satisfied (more components; p<0.05) and had significantly more normal or near-normal range of arm motion (93 vs. 84%, p=0.037). (Several subgroup analyses: Women with poor social support were most likely to benefit from the nurse CM intervention. ) Uncertainty: Intervention group had less uncertainty at 1, 3 and 6 months (p<0.05). Effect size not specified. Mood and well-being: no sign. diff. between int. and control group. Overall costs: no difference found including subgroup analyses. (Some subgroups benefitted significantly from APN, e.g. unmarried women and women with no family history of breast cancer).

c) QoL:? Cost data: N=152 (n-int=78, n- contro=74; 58 excluded because of missing data) a) Primary analyses: repeated measures and analysis of variance for each dependent variable (univariate mixed model and multivariate model). Plot of means for the core measures. b) Yes. No difference on demographics, Starting points for depending variables were discrepant for which reason adjustment was performed (Potential bias of adj. was discussed). c) Patient psychosocial responses: 78 patients completing four interviews (numbers in each group not stated). Number of hospitalizations: 77 of 78 completing four interviews (n- OHC=24, n-shc=27, n-oc=26). LOS: 52 (had been hospitalized) of 78 completing four interviews (n- OHC=14, n-shc=18, n-oc=20). Cost of APN services were based on time logs. [25] a) Three-arm simple randomization b) N=166, Numbers assigned to each of the arms N/A. -Measures of Patient Psychosocial Responses (Five interviews at 6-week interval; first before group assignment.) -Number of hospitalizations -Length of Stay (LOS) (continuously through 24 weeks). -Psychosocial responses: Interview questionnaire (in-person or telephone?); Scales: Symptom distress (The Symptom Distress Scale); Pain(McGill- Melzack Pain Questionnaire); Current Concerns (Weisman and Worden s Inventory of Current Concerns); Mood state (Profile of Mood States) Functional status (General Health Rating Index) (ref to all above) -A Medical Record Review Instrument was developed. Psychosocial Responses : Significant difference between the profiles of the two nursing groups and the office care group with regards to adjusted Symptom Distress (P=0.03) and adjusted Enforced Social Dependency (P=0.02) in favour of home care nursing. The OC group rather steadily reported improved health perceptions over time, whereas the two treatment groups reported worse health perceptions (p<0.05). No of hospitalizations and LOS: No significant differences

a) Stratified log-rank test was used to compare groups. Kaplan-Meier curves stratified by stage of disease at diagnosis. Cox s proportional hazards regression model to compute adjusted hazard ratios (=HR; Proportional hazards assumption was Schoenfeld tested) b) Yes (demographics and clinical variables; more late stage patients in intervention group (p=0,013). Adjusted and stratified analyses performed. c) Survival status for all 375 included patients were obtained Psychosocial questionnaire responderse: time 0: n-int=190 n- UC=185; time 3 months: n-int=163, n- UC= 153; time 6 months: n-int=158, n- UC=147). [24] a) Simple randomization. b) N=375, n- intervention=190, n- control=185 Primary: Length of survival (up to 44 months of follow up) Secondary: To identify psychosocial and clinical predictors of patient survival (i.e. depressive symptoms, symptom distress, functional status, co-morbidities, length of hospital stay, age, and cancer stage). (baseline, 3, and 6 months) Survival status was ascertained by letter, telephone, or death certificates (?) Demographics: obtained at accrual (?) Stage of disease: Surgical pathology reports and physician s discharge summary (?) Psychosocial questionnaires : Center for Epidemiological Studies-Depression Scale (CES- D), Symptom Distress Scale (SDS), and Enforced Social Dependency Scale (ESDS) (ref to all) Non-stratified analyses revealed no difference in survival status between groups (p=0,129). Stratified analyses: Late-stage patients 2-year survival were 66.7% in int. group vs. 39.6% in control group (p<0.05). Adjusted for psychosocial and clinical covariates: Usual care had death-hr=2.04 (95% CI 1.33-3.12, p=0.001) Late stage usual care patients had adjusted death-hr=4.55 (CI 2.92-7.08; p<0.001) of psychosocial questionnaires were not mentioned at all in results paragraph.

a) -Patients evaluations: Scores were examined for effects of group, time, and group-by-time interaction using a random effects regression model. -Surrogates exp.: Post-intervention scores t-test compared. -AD: Chi-square comparison and t-test. Kaplan-Meier curves comparison of group membership and time to completion of ADs. -Costs: F test Effect sizes were calculated for most outcomes. b) Yes, (Patients demographics and diagnoses (and later survival), no diff.; surrogates: No of participants, sex and relationship: no diff.) c) Patients and surrogates evaluations:? Mean per case AICCP costs: Data for 70 VAMC patients. Other costs:169 VAMC patients (AICCP=93, UC=76). AD etc: data on 180 VAMC patients (AICCP= 85 and UC=95) d) Yes, all outcomes (18 patients crossed over to AICCP, two patients crossed over to UC. Some VAMCs inpatient units implemented AICCP as usual care during the study) [26] a) Block-randomization (blocks of 10; rationale not outlined) b) N=275; n- AICCP=133, n- UC=142 ; N-surrogates (relatives)=168, n- saiccp =76, n- suc=92. -Patients evaluations of patient/provider communication, satisfaction with care and attitudes about participation in treatment planning (enrolment, at 3 and 6 months) -Surrogates experiences with the health care system. (3 months post-enrolment.) -Costs (end of study) -Advance directives (AD) and do-not-resuscitate and intubate (DNR[I]) (enrolment, 3 and 6 months) Patient/provider communication, satisfaction with care: Investigator-constructed, 10-item scale (?, but reliability tested on enrolment ) Participation in treatment planning was assessed by a single item (?; asked questionnaire or interview?) Surrogates experiences (problems in 7 domains were averaged to create a single overall rating): Modified EOL Family Interview (ref; asked - questionnaire or interview?) Costs: Program contact, salary, and overhead costs collected from 3 sites (the VAMC patients). Other costs: medical records for VAMCs patients. AD and DNR(I): VAMC participants medical records Patient satisfaction with care: Significant group-by-time interaction in favour of the AICCP group (Effect size 0.18, P = 0.03). (Effect size is the ratio of the estimated treatment effect.) Surrogates post-test scores: Fewer problems (with the spiritual and emotional support delivered) reported by AICCP surrogates than UC surrogates (effect size 0.39, p=0.03) Costs: no stat. sign diff. AD: Median time to completion of first AD: AICCP=46 days vs. UC= 238 days (log-rank P=0.02) Proportion of patients having completed at least one AD, and the mean numbers of ADs per patient were sign. higher for the AICCP group at both 3 and 6 months (p=0.01).

[22] a) Stratified randomisation (six strata; three strata based on unmet need status, and two strata based on gender). b) N=259, n-cm=130, n-control=129 [27] a) Stratified randomisation according to hospital and treatment intent (rationale and numbers of strata not outlined) b) N=203 (n-nurse led follow-up=100, n- control=103) -Unmet needs (assessed by patients) -Reported symptom severity -Several dimensions of QoL -Formal service utilization (Data collection: At baseline, at 3 and 6 months) Primary: QoL and patients satisfaction at three months (assessed at baseline, 3, 6, and 12 months) Secondary: Overall survival, Symptomfree survival, Progressionfree survival. GPs satisfaction (at the end of study participation). Service use (3, 6 and 12 months) and cost effectiveness -Aspects of daily living (three unmet needs-categories) (ref); -Standard questions on symptom severity (?) -Spitzer s physical QoL Index (ref), five-item mood state score from SF-36 (ref), and a specially developed 4-item scale measuring patient experienced disruptions in treatment (?) All above: Telephone interviews -Service utilization: Patients reports and audit of patients medical records. -EORTC QLQ-C30 and module about lung cancer. (ref) -Patient satisfaction questionnaire incorporating three validated measures and tested in a pilot study (ref) No information on source of secondary outcomes. a) Chi-square and analysis of variance to test differences between intervention and control groups b) yes (no difference found on baseline demographic, medical and need status) d) 3 months: n-cm=109, n- control=108, 6 months: n-cm=93, n- control=92 e) Not mentioned; unclear if 11 CM group patients who refused CM services were followed up and in which group they were analysed (?) a) QoL + satisfaction: Mann-Whitney U test Survival: Kaplan-Meier Costs: Mann-Whitney U test. b) Yes (no difference found on clinical, OoL and pat sat baseline variables) c) 3 months: n-int=76, n-control=74; 6 months: n-int=53, n-control= 58; 12 months: n-int=26, n-control=29, but it was mentioned that no intervention group patients reverted to medical follow-up.? Not to be found in the article * of interest: if primary and secondary was not indicated, - are used in front of each # Validity account categorised as follows:?: validity not mentioned at all; ref: reference(s) quoted; yes: it is mentioned that measure is validated No statistically significant differences were observed on any outcome measure for the overall sample as well as for selected atrisk patient subgroups. Int. group had less dyspnoea (p=0,03; a QoL score) and significantly higher satisfaction in each subscale at three months. Int. group had longer time to symptomatic progression (p=0,01). Significant change in pattern of service use, but no difference in readmission rates. Significantly more patients in int. group died at home (p=0,04). No difference in costs, and GP satisfaction.